Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Matching Therapy Guided by MTB in Advanced Solid Tumors
NCT06739395Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib, temozolomide, anlotinib, trametinib, dabrafenib + trametinib and 7 more in solid tumor (9 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Progression Free Survival 2 / Progression Free Survival 1 Ratio at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
olaparibtemozolomideanlotinibtrametinibdabrafenib + trametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06739395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739395.